NCT07119190Not yet recruiting
A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy
Construction of a Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy
Source: ClinicalTrials.gov · Last updated 12 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this study is to develop and refine an integrated minimally invasive care pathway for resectable lung cancer in the immunotherapy era, establishing a novel precision perioperative immunotherapy paradigm encompassing original techniques and clinical applications.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 15 Jul 2025
- Start date
- 6 Aug 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07119190
What you commit to
- Study type: Observational
- Planned participants: 350
- From 6 Aug 2025 to the primary completion date, 30 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Histology of other malignant tumors, including concurrent malignant tumors of other organ systems;
Other illness
- Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC);
- Severe organ dysfunction (e.g. cardiac or renal insufficiency);
Other
- Pregnancy or lactation;
- Insufficient sample quality;
- Other judgments by the Investigator that the patient should not participate in the study.
Who the study is looking for
- Age ≥ 18 years old;
- NSCLC patients underwent radical surgical resection;
- Adequate clinical-pathologic data, imaging data and follow-up data obtainable for multi-omics analysis;
- Scheduled for or currently receiving neoadjuvant/perioperative immunotherapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.